schizandrin a has been researched along with docetaxel anhydrous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, X; Gao, C; Liu, L; Qu, D; Shi, F; Su, X; Wang, C | 1 |
1 other study(ies) available for schizandrin a and docetaxel anhydrous
| Article | Year |
|---|---|
A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cyclooctanes; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Esophageal Neoplasms; Humans; Inhibitory Concentration 50; Lignans; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polycyclic Compounds; Solubility; Surface Properties; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |